Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated:  8/28/2015
Gottschalk Medical Plaza, 1 Medical Plaza Drive
mi
from
Irvine, CA
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated: 8/28/2015
Gottschalk Medical Plaza, 1 Medical Plaza Drive
mi
from
Irvine, CA
Click here to add this to my saved trials
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Boston, MA
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Nashville, TN
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated:  9/1/2015
Clinical Research Facility
mi
from
Dallas, TX
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
A Multi-center, Open-label, Study to Investigate the Pharmacokinetic Interaction of RO5185426 With a "Cocktail" of Five Probe Drugs for CYP450 Dependent Metabolism in Patients With Previously Treated and Untreated Metastatic Melanoma
Status: Enrolling
Updated: 9/1/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Status: Enrolling
Updated:  9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
Status: Enrolling
Updated: 9/23/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
A Phase I Study of Poly IC:LC and NY-ESO-1/gp100 Peptides Either Emulsified With Montanide ISA 51 or in Aqueous Solution With Escalating Doses of CP 870,893 in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma
Status: Enrolling
Updated:  9/23/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
A Phase I Study of Poly IC:LC and NY-ESO-1/gp100 Peptides Either Emulsified With Montanide ISA 51 or in Aqueous Solution With Escalating Doses of CP 870,893 in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma
Status: Enrolling
Updated: 9/23/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Harry & Jeanette Weinberg Cancer Inst At Franklin Square
mi
from
Baltimore, MD
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Harry & Jeanette Weinberg Cancer Inst At Franklin Square
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Dana-Farber Cancer Inst
mi
from
Boston, MA
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Dana-Farber Cancer Inst
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Mem Sloan-Ket Can Ctr
mi
from
New York, NY
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Mem Sloan-Ket Can Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Blumenthal Cancer Center at Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Providence Portland Medical Center
mi
from
Portland, OR
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
The University Of Texas
mi
from
Houston, TX
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
The University Of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Calgary,
Phase II, 2nd Line Melanoma - RAND Monotherapy
A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Calgary,
Click here to add this to my saved trials
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
INST 0814: The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
Status: Enrolling
Updated:  9/24/2015
Universtiy of New Mexico Cancer Center
mi
from
Albuquerque, NM
The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
INST 0814: The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure
Status: Enrolling
Updated: 9/24/2015
Universtiy of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Structure of the Herpes Simplex Virus Receptor
Polymorphism of the Herpes Simplex Virus Receptor
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Structure of the Herpes Simplex Virus Receptor
Polymorphism of the Herpes Simplex Virus Receptor
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated:  9/26/2015
Arizona Cancer Center
mi
from
Tucson, AZ
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated: 9/26/2015
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated:  9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated: 9/26/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated:  9/26/2015
University of Michigan
mi
from
Ann Arbor, MI
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated: 9/26/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated:  9/26/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated: 9/26/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated:  9/26/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated: 9/26/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated:  9/26/2015
Helsinki University Central Hospital
mi
from
Helsinki,
Microarray Analysis for Human Genetic Disease
Microarray Analysis for Human Genetic Disease
Status: Enrolling
Updated: 9/26/2015
Helsinki University Central Hospital
mi
from
Helsinki,
Click here to add this to my saved trials
Natural History Study of Moles and Suspicious Melanoma
Dermoscopic Diagnosis, Histopathological Correlation, and Cellular Immortalization of Melanocytic Nevi and Primary Cutaneous Melanoma
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Natural History Study of Moles and Suspicious Melanoma
Dermoscopic Diagnosis, Histopathological Correlation, and Cellular Immortalization of Melanocytic Nevi and Primary Cutaneous Melanoma
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Genetic Analysis of Familial Melanoma
Genetic Analysis of Familial Melanoma
Status: Enrolling
Updated:  9/26/2015
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Genetic Analysis of Familial Melanoma
Genetic Analysis of Familial Melanoma
Status: Enrolling
Updated: 9/26/2015
National Human Genome Research Institute (NHGRI), 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated:  9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated: 9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin
Status: Enrolling
Updated:  9/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma
Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin
Status: Enrolling
Updated: 9/28/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis
Status: Enrolling
Updated:  9/28/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
The Role of TAB3 Protein in Tumorigenesis
Status: Enrolling
Updated: 9/28/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Mercy Hospital Fort Smith
mi
from
Ft. Smith, AR
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Mercy Hospital Fort Smith
mi
from
Ft. Smith, AR
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Marin Cancer Care, Inc.
mi
from
Greenbrae, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Marin Cancer Care, Inc.
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Bay Area Tumor Institute
mi
from
Oakland, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Saint Joseph Hospital - Orange
mi
from
Orange, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Saint Joseph Hospital - Orange
mi
from
Orange, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Stanford Cancer Institute
mi
from
Palo Alto, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Stanford Cancer Institute
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Kaiser Permanente-Redwood City
mi
from
Redwood City, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Kaiser Permanente-Richmond
mi
from
Richmond, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Kaiser Permanente-Richmond
mi
from
Richmond, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Kaiser Permanente Roseville
mi
from
Roseville, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Kaiser Permanente Roseville
mi
from
Roseville, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Kaiser Permanente - Sacramento
mi
from
Sacramento, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Kaiser Permanente - Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Kaiser Permanente-San Diego Mission
mi
from
San Diego, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Kaiser Permanente-San Diego Mission
mi
from
San Diego, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Veterans Administration-San Diego Medical Center
mi
from
San Diego, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Veterans Administration-San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated:  9/28/2015
Kaiser Permanente-San Francisco
mi
from
San Francisco, CA
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma
Status: Enrolling
Updated: 9/28/2015
Kaiser Permanente-San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials